ClinicalTrials.gg
Active, not recruitingNCT03623074CYPRESSUpdated May 5, 2026

Control of Myopia Using Novel Spectacle Lens Designs

An interventional study of Novel spectacle lens design and Spectacle lenses in Juvenile Myopia, sponsored by SightGlass Vision, Inc.. Active, not recruiting at 14 sites in 2 countries. Open to participants aged 6 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by SightGlass Vision, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
6 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Myopia by SightGlass Vision, Inc. — 3 open to participants now, 12 under way, none of them phase 3. Myopia · SightGlass Vision, Inc..

Enrollment
2nd of 14
266 · median 71
Started
2018
with 2 others
No phase
14 of 14
3 open now
Primary completion
2022-05
later than 1 of 11 live
Registered
1st of 14
by date

Among the 14 studies in Myopia by SightGlass Vision, Inc., this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 14 with no phase, reaches primary completion later than 1 of the 11 other live ones, and was the 1st registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

3 of the 14 studies in Myopia by SightGlass Vision, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 10 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Myopia by SightGlass Vision, Inc., or all of them as a file.
02

Study summary

Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile myopia.

03

Conditions studied

  • Juvenile Myopia

Browse trials for

Keywords

  • Myopia
04

Who can participate

Ages eligible
6 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children 6-10 years of age (day prior to 10th birthday) at time of /assent
  • SER error between -0.75 and -4.50 D
  • SER power between the two eyes must be less than or equal to 1.50 D
  • Willingness to participate in the trial for 3 years without content lens wear

Exclusion criteria

Exclusion Criteria:

  • Previous or current use of contact lenses
  • Previous or current use of bifocals, progressive addition spectacles lenses
  • Previous or current use of myopia control treatment
  • Astigmatism worse then -1.25 DC in either eye
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    Test Arm 1

    Single vision, impact-resistant spectacle lenses

    Device: Novel spectacle lens design

  • Experimental
    Test Arm 2

    Single vision, impact-resistant spectacle lenses

    Device: Novel spectacle lens design

  • Other
    Test Arm 3

    Single vision, impact-resistant spectacle lenses

    Device: Spectacle lenses

Interventions

  • DeviceNovel spectacle lens design

    Use of lenses may reduce the rate of progression of juvenile myopia

  • DeviceSpectacle lenses

    Use of lenses may reduce the rate of progression of juvenile myopia

06

What researchers measure

Primary outcomes

  1. Axial length

    Change in axial length from baseline

    Time frame: 36 Months

  2. Spherical equivalent refraction

    Change in spherical equivalent refraction from baseline

    Time frame: 36 Months

07

Study locations

14 sites
  • Golden Optometric Group
    Whittier, California 90606, United States
  • Sabal Eye Care
    Longwood, Florida 32779, United States
  • Visual Performance Center
    Pensacola, Florida 32503, United States
  • Kannarr Eye Care
    Pittsburg, Kansas 66762, United States
  • Eye Associates of Northeast Louisiana (DBA Haik Humble Eye Center) Research Dept
    West Monroe, Louisiana 71291, United States
  • Advanced Eyecare, PC
    Raytown, Missouri 64133, United States
  • SUNY School of Optometry
    New York, New York 10036, United States
  • Sacco Eye Group
    Vestal, New York 13850, United States
  • Dept of Clinical Research, South Shore Eye Care, LLP
    Wantagh, New York 11793, United States
  • Dunes Eye Consultants
    Dakota Dunes, South Dakota 57049, United States
  • Total Eye Care
    Memphis, Tennessee 38119, United States
  • University of Houston College of Optometry
    Houston, Texas 77204, United States
  • William J Bogus, OD, FAAO
    Salt Lake City, Utah 84106, United States
  • Center for Ocular Research & Education, School of Optometry, University of Waterloo School of Optometry & Vision Science
    Waterloo, Ontario N2L 3G1, Canada
08

References and documents

Publications

  • Laughton D, Hill JS, McParland M, Tasso V, Woods J, Zhu X, Young G, Craven R, Hunt C, Neitz J, Neitz M, Chalberg TW, Jones D, Wolffsohn JS. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS). BMJ Open Ophthalmol. 2024 Oct 9;9(1):e001790. doi: 10.1136/bmjophth-2024-001790. PubMed 39384223 ↗
  • Rappon J, Chung C, Young G, Hunt C, Neitz J, Neitz M, Chalberg T. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023 Nov;107(11):1709-1715. doi: 10.1136/bjo-2021-321005. Epub 2022 Sep 1. PubMed 36126105 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in May 2022, 45 months.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 45 months is above that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2018
First posted
Aug 9, 2018
StartActual
Jul 16, 2018
Primary completionActual
May 15, 2022
CompletionEst.
Dec 31, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03623074
Lead sponsor
SightGlass Vision, Inc.
Responsible party
Sponsor
First posted
Aug 9, 2018
Start date
Jul 16, 2018
Primary completion
May 15, 2022
Completion
Dec 31, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Joseph Rappon, OD, MS, FAAO
study chair · SightGlass Vision, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion